Business Context and Reporting Period
This Form 8-K Current Report was filed by MacroGenics, Inc. on February 10, 2021. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on management appointments rather than financial performance results.
Material Changes
The material change reported is the appointment of Federica O'Brien as a director, effective immediately. Key details include:
- Role: Class I Director serving until the 2023 Annual Meeting of Stockholders.
- Committee Assignment: Appointed to the Audit Committee.
- Compensation: Annual retainer of $40,000 (prorated from appointment date).
- Equity Grant: Option to purchase 30,000 shares of common stock at an exercise price of $21.50 per share.
- Vesting Schedule: 12 substantially equal monthly portions beginning on the first monthly anniversary of the grant date.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies are disclosed in this document other than standard governance disclosures. The filing confirms there are no undisclosed arrangements or transactions in which Ms. O'Brien has a material interest.
Key Facts for Investor Verification
- Verify the impact of the new Audit Committee member on the company's financial oversight.
- Confirm the dilution effect of the 30,000 share option grant on existing shareholders.
- Review the attached press release (Exhibit 99.1) for additional context on Ms. O'Brien's qualifications.
- Note that this filing does not contain updated financial statements or operational metrics.